

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Three

Details of transactions requiring disclosure-

(1)

Date of transaction:

1 September 2020

Nature of transaction:

Transfer of legal title to 107,106 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Gordon Neil MacLeod, in accordance with such terms

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

N/A

Number of financial products to which the transaction related:

107,106

(2)

Date of transaction:

1 September 2020

Nature of transaction:

Acquisition of beneficial interest in 88,925 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

\$1,200,000 (being \$13.468 per share)

Number of financial products to which the transaction related:

88,925

(3)

Date of transaction:

1 September 2020

Nature of transaction:

On market sale

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

\$953,588 (being \$13.468 per share)

Number of financial products to which the transaction related:

70,804

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

N/A

Nature of relevant interest:

For that relevant interest, -

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	8 September 2020
Date of last disclosure:	21 August 2019

Director or senior manager giving disclosure

Full name(s):	David Bennett
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Financial Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

(1)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	96,893
Number held in class after acquisition or disposal:	119,934
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (held as bare trustees)
Registered holder(s) once transfers are registered:	N/A

(2)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
For that relevant interest-	
Number held in class before acquisition or disposal:	32,724
Number held in class after acquisition or disposal:	32,724
Current registered holder(s):	David Bennett
Registered holder(s) once transfers are registered:	N/A

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative, -</i>	
Parties to the derivative:	

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Three

Details of transactions requiring disclosure-

(1)

Date of transaction:

1 September 2020

--

Transfer of legal title to 21,421 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to David Bennett, in accordance with such terms

Nature of transaction:

N/A

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

N/A

Number of financial products to which the transaction related:

21,421

(2)

Date of transaction:

1 September 2020

--

Acquisition of beneficial interest in 44,462 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Nature of transaction:

N/A

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

\$600,000 (being \$13.468 per share)

Number of financial products to which the transaction related:

44,462

(3)

Date of transaction:

1 September 2020

Nature of transaction:

On market sale

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

\$288,498 (being \$13.468 per share)

Number of financial products to which the transaction related:

21,421

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

N/A

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

--

For a derivative relevant interest,-

Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

For that derivative relevant interest,-

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

8 September 2020

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.

[illegible]

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Three

Details of transactions requiring disclosure-

(1)

Date of transaction:

1 September 2020

Transfer of legal title to 42,842 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Tom Brownrigg, in accordance with such terms

Nature of transaction:

N/A

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

42,842

(2)

Date of transaction:

1 September 2020

Acquisition of beneficial interest in 44,462 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Nature of transaction:

N/A

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$600,000 (being \$13.468 per share)

Number of financial products to which the transaction related:

44,462

(3)

Date of transaction:

1 September 2020

Nature of transaction:

On market sale

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$576,996 (being \$13.468 per share)

Number of financial products to which the transaction related:

42,842

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

N/A

Nature of relevant interest:

For that relevant interest,-


Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer: 
Date of signature: 8/9/20
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:

8 September 2020

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

Ryman Healthcare Limited
8 September 2020
28 January 2020

Nicole Forster
Ryman Healthcare Limited
Chief People and Technology Officer

(1)

Ordinary shares (NZX code: RYM)	
Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme	
	89,209
	67,788
David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (held as bare trustees)	
N/A	

Ordinary shares (NZX code: RYM)	
Registered holder and beneficial owner	
	18,07
	39,49
Nicole Forster	
N/A	

[illegible]

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

One

Details of transactions requiring disclosure-

(1)

Date of transaction:

1 September 2020

Nature of transaction:

Transfer of legal title to 21,421 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Nicole Forster, in accordance with such terms

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

N/A

Number of financial products to which the transaction related:

21,421

(2)

Date of transaction:

N/A

Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

(3)

Date of transaction:

N/A

Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:

Details of derivative,-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer: 

Date of signature: 8/9/20

8 September 2020

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	8 September 2020
Date of last disclosure:	17 January 2020

Director or senior manager giving disclosure

Full name(s):	Jeremy Moore
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Development Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

(1)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	61,257
Number held in class after acquisition or disposal:	89,653
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (as bare trustees)
Registered holder(s) once transfers are registered:	N/A

(2)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
For that relevant interest-	
Number held in class before acquisition or disposal:	10,450
Number held in class after acquisition or disposal:	0
Current registered holder(s):	Jeremy Moore
Registered holder(s) once transfers are registered:	N/A

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Three

Details of transactions requiring disclosure-

(1)

Date of transaction:

1 September 2020

Nature of transaction:

Transfer of legal title to 16,066 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme to Jeremy Moore, in accordance with such terms

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

N/A

Number of financial products to which the transaction related:

16,066

(2)

Date of transaction:

1 September 2020

Nature of transaction:

Acquisition of beneficial interest in 44,462 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

\$600,000 (being \$13.468 per share)

Number of financial products to which the transaction related:

44,462

(3)

Date of transaction:

1 September 2020

Nature of transaction:

On market sale

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

\$357,117 (being \$13.468 per share)

Number of financial products to which the transaction related:

26,516

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

N/A

Nature of relevant interest:

For that relevant interest,-


Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative relevant interest,-</i>	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature:	8 September 2020
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	8 September 2020
Date of last disclosure:	N/A

Director or senior manager giving disclosure

Full name(s):	Cheyne Chalmers
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Operations Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

(1)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	0
Number held in class after acquisition or disposal:	40,751
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (as bare trustees)
Registered holder(s) once transfers are registered:	N/A

(2)

Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
For that relevant interest-	
Number held in class before acquisition or disposal:	0
Number held in class after acquisition or disposal:	1,474
Current registered holder(s):	Cheyne Chalmers
Registered holder(s) once transfers are registered:	N/A

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
<i>For that derivative,-</i>	
Parties to the derivative:	

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Two

Details of transactions requiring disclosure-

(1)

Date of transaction:

1 September 2020

Nature of transaction:

Acquisition of beneficial interest in 1,474 ordinary shares, subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$20,000 (being \$13.468 per share)

Number of financial products to which the transaction related:

1,474

(2)

Date of transaction:

1 September 2020

Nature of transaction:

Acquisition of beneficial interest in 40,757 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$550,000 (being \$13.468 per share)

Number of financial products to which the transaction related:

40,757

(3)

Date of transaction:

N/A

Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

N/A

Nature of relevant interest:

For that relevant interest,-

Number held in class:

Current registered holder(s):

For a derivative relevant interest,-

Type of derivative:

Details of derivative,-


The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

--

A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:


8 September 2020

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	8 September 2020
Date of last disclosure:	N/A

Director or senior manager giving disclosure

Full name(s):	Mary-Anne Stone
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Acting Chief Sales and Marketing Officer

Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

(1)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	0
Number held in class after acquisition or disposal:	22,231
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (as bare trustees)
Registered holder(s) once transfers are registered:	N/A

(2)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
For that relevant interest-	
Number held in class before acquisition or disposal:	0
Number held in class after acquisition or disposal:	1,486
Current registered holder(s):	Mary-Anne Stone
Registered holder(s) once transfers are registered:	N/A

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	

8/9
A

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

--

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Two

Details of transactions requiring disclosure-

(1)

Date of transaction:

1 September 2020

Nature of transaction:

Acquisition of beneficial interest in 1,486 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$20,000 (being \$13.360 per share)

Number of financial products to which the transaction related:

1,486

(2)

Date of transaction:

1 September 2020

Nature of transaction:

Acquisition of beneficial interest in 22,231 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme

Name of any other party or parties to the transaction (if known):

N/A

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

\$300,000 (being \$13.468 per share)

Number of financial products to which the transaction related:

22,231

(3)

Date of transaction:

N/A

Nature of transaction:

Name of any other party or parties to the transaction (if known):

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:

Number of financial products to which the transaction related:

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—

Whether relevant interests were acquired or disposed of during a closed period:

No

Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products:

N/A

Nature of relevant interest:

For that relevant interest, -

Number held in class:

Current registered holder(s):

For a derivative relevant interest, -

Type of derivative:

Details of derivative, -


The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

8/9

A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
For that derivative relevant interest,-
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Certification

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
Signature of director or officer:
Date of signature:
or
Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:


8 September 2020

Notes

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.